Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimization of Erlotinib for the Treatment of Patients With Advanced Non Small Cell Lung Cancer: an Italian Randomized Trial

NCT00637910 is registered in ClinicalTrials.gov with Fatebenefratelli and Ophthalmic Hospital as lead sponsor.

NCT NCT00637910
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00637910 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimization of Erlotinib for the Treatment of Patients With Advanced Non Small Cell Lung Cancer: an Italian Randomized Trial
Lead sponsor
Fatebenefratelli and Ophthalmic Hospital
Phase
Phase 3
Overall status
Unknown status
Start date
November 30, 2007
Completion date
February 28, 2013
Enrollment
850 (estimated)
Sites
105

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer (nsclc)